Shattuck Labs Inc banner

Shattuck Labs Inc
NASDAQ:STTK

Watchlist Manager
Shattuck Labs Inc Logo
Shattuck Labs Inc
NASDAQ:STTK
Watchlist
Price: 4.05 USD -5.37% Market Closed
Market Cap: $256.3m

Shattuck Labs Inc
Other

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Shattuck Labs Inc
Other Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other CAGR 3Y CAGR 5Y CAGR 10Y
Shattuck Labs Inc
NASDAQ:STTK
Other
-$451k
CAGR 3-Years
N/A
CAGR 5-Years
-50%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other
$47m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Other
-$6.5B
CAGR 3-Years
-235%
CAGR 5-Years
-116%
CAGR 10-Years
-5%
Amgen Inc
NASDAQ:AMGN
Other
-$10.9B
CAGR 3-Years
-372%
CAGR 5-Years
-161%
CAGR 10-Years
-34%
Astria Therapeutics Inc
NASDAQ:ATXS
Other
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other
-$371.2m
CAGR 3-Years
-30%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
No Stocks Found

Shattuck Labs Inc
Glance View

Market Cap
256.3m USD
Industry
Biotechnology

Shattuck Labs, Inc. engages in the research and development of Agonist Redirected Checkpoint (ARC) platform. The company is headquartered in Austin, Texas and currently employs 85 full-time employees. The company went IPO on 2020-10-09. The firm is engaged in the development of dual-sided fusion proteins. The firm has created an approach to immune modulation by designing biologics with structural characteristics. Compounds derived from its Agonist Redirected Checkpoint (ARC) platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the cluster of differentiation 47/signal regulatory protein alpha (CD47/SIRPa) checkpoint interaction to restore an anti-tumor immune response and to activate the cluster of differentiation 40 (CD40) costimulatory receptor to bolster an immune response. The firm's second product candidate, SL-279252, is designed to simultaneously inhibit the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction and activate the OX40 receptor.

STTK Intrinsic Value
HIDDEN
Show

See Also

What is Shattuck Labs Inc's Other?
Other
-451k USD

Based on the financial report for Dec 31, 2024, Shattuck Labs Inc's Other amounts to -451k USD.

What is Shattuck Labs Inc's Other growth rate?
Other CAGR 5Y
-50%

Over the last year, the Other growth was -751%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett